Drug Patents owned by Jazz

1. List of Sunosi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10351517 JAZZ Treatment of sleep-wake disorders
Jun, 2026

(3 years from now)

US9604917 JAZZ Treatment of sleep-wake disorders
Jun, 2026

(3 years from now)

US8877806 JAZZ Treatment of sleep-wake disorders
Jun, 2026

(3 years from now)

US8440715 JAZZ Treatment of sleep-wake disorders
Aug, 2027

(4 years from now)

US10512609 JAZZ Formulations of (R)-2-amino-3-phenylpropyl carbamate
Sep, 2037

(14 years from now)

US10195151 JAZZ Formulations of (R)-2-amino-3-phenylpropyl carbamate
Sep, 2037

(14 years from now)

US10912754 JAZZ Methods and compositions for treating excessive sleepiness
Jun, 2038

(15 years from now)

US10959976 JAZZ Methods and compositions for treating excessive sleepiness
Jun, 2038

(15 years from now)

US10940133 JAZZ Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(17 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 17, 2024
Orphan Drug Exclusivity (ODE) Jun 17, 2026

Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient

NCE-1 date: June, 2023

Market Authorisation Date: 17 June, 2019

Treatment: To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa); Treatment of excessive daytime sleepiness associated with obstructive sleep apnea (osa) in an adult through a dosing regimen that includes oral administration of 75 mg once daily for at least 3 days followed by 150 mg once daily; To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa) with a dosing regimen that includes a dose of 75 mg once daily for at least 3 days followed by 150 mg once daily; Treatment of excessive daytime sleepiness associated with obstructive sleep apnea (osa) in a patient with moderate renal impairment

Dosage: TABLET;ORAL

More Information on Dosage

2. List of Xywav drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8731963 JAZZ Sensitive drug distribution system and method
Dec, 2022

(a month ago)

US8731963

(Pediatric)

JAZZ Sensitive drug distribution system and method
Jun, 2023

(4 months from now)

US9132107 JAZZ Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
Jan, 2033

(9 years from now)

US10675258 JAZZ Method of using gamma-hydroxybutyrate compositions for the treatment of disorders
Jan, 2033

(9 years from now)

US8901173 JAZZ Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
Jan, 2033

(9 years from now)

US10195168 JAZZ Gamma-hydroxybutyrate compositions and their uses for the treatment of disorders
Jan, 2033

(9 years from now)

US8591922 JAZZ Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
Jan, 2033

(9 years from now)

US9486426 JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mar, 2033

(10 years from now)

US10864181 JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mar, 2033

(10 years from now)

US11253494 JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mar, 2033

(10 years from now)

US8772306 JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mar, 2033

(10 years from now)

US10213400 JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mar, 2033

(10 years from now)

US9050302 JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mar, 2033

(10 years from now)

US10864181

(Pediatric)

JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Sep, 2033

(10 years from now)

US9486426

(Pediatric)

JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Sep, 2033

(10 years from now)

US11253494

(Pediatric)

JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Sep, 2033

(10 years from now)

US9050302

(Pediatric)

JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Sep, 2033

(10 years from now)

US10213400

(Pediatric)

JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Sep, 2033

(10 years from now)

US8772306

(Pediatric)

JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Sep, 2033

(10 years from now)

US11426373 JAZZ Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
Sep, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 12, 2028
New Product (NP) Jul 21, 2023
New Indication (I) Aug 12, 2024

Drugs and Companies using CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE ingredient

Market Authorisation Date: 21 July, 2020

Treatment: Method of treating a patient with a prescription drug using a computer database in a computer system for distribution; Treatment of cataplexy or excessive daytime sleepiness (eds) in patients 7 years of age and older with narcolepsy with a mixture of sodium, potassium, magnesium, and calcium salts of ghb; Method of treating excessive daytime sleepiness and/or cataplexy in narcolepsy patients with sodium oxybate when divalproex sodium is concomitantly administered.; Method of treating excessive daytime sleepiness and/or cataplexy in narcolepsy patients with a salt of gamma-hydroxybutyrate when divalproex sodium is concomitantly administered; Method of reducing adverse effects in patients who are concomitantly administered a salt of gamma-hydroxybutyrate and divalproex sodium; Method of treating patients with a salt of gamma-hydroxybutyrate when divalproex sodium is concomitantly administered; Method of treating patients with idiopathic hypersomnia with sodium oxybate when divalproex sodium is concomitantly administered; Method of reducing adverse effects in patients suffering from excessive daytime sleepiness and/or cataplexy in narcolepsy who are concomitantly administered sodium oxybate and divalproex sodium; Treatment of cataplexy or excessive daytime sleepiness (eds) in patients 7 years of age and older with narcolepsy with a mixture of sodium, potassium, magnesium, and calcium salts of ghb administered between 2 and 4 hours after eating

Dosage: SOLUTION;ORAL

How can I launch a generic of XYWAV before it's patent expiration?
More Information on Dosage

3. List of Zepzelca drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7763615 JAZZ Ecteinascidin analogs for use as antitumour agents
Dec, 2024

(1 year, 10 months from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 15, 2025
Orphan Drug Exclusivity (ODE) Jun 15, 2027

Drugs and Companies using LURBINECTEDIN ingredient

NCE-1 date: June, 2024

Market Authorisation Date: 15 June, 2020

Treatment: Treatment of adult patients with small cell lung cancer (sclc) with disease progression on or after platinum-based chemotherapy.

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in